Quick Answer
Barinthus Biotherapeutics plc. reported Operating Income of -$70.56 million for fiscal year 2025.
Barinthus Biotherapeutics plc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$70.56M | -3.8% |
| 2024 | -$67.97M | +19.0% |
| 2023 | -$83.91M | -1976.6% |
| 2022 | -$4.04M | +91.1% |
| 2021 | -$45.22M | -125.6% |
| 2020 | -$20.05M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.07M | -60.6% | +35.4% |
| June 30, 2025 | -$23.32M | -27.6% | -13.2% |
| March 31, 2025 | -$20.60M | -21.8% | -119.6% |
| September 30, 2024 | -$9.38M | +41.8% | +48.7% |
| June 30, 2024 | -$18.29M | +30.6% | -8.1% |
| March 31, 2024 | -$16.91M | +21.3% | -5.0% |
| September 30, 2023 | -$16.11M | -322.6% | +38.9% |
| June 30, 2023 | -$26.34M | -299.0% | -22.6% |
- Barinthus Biotherapeutics plc. showed a decrease of -3.8% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Barinthus Biotherapeutics plc.’s operating income has declined by 252.0% (from -$20.05 million to -$70.56 million).
- The most recent figure is from Barinthus Biotherapeutics plc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: